<DOC>
	<DOCNO>NCT00481364</DOCNO>
	<brief_summary>This prospective , randomize , control study aim investigate effect atorvastatin treatment hemodialysis patient concern progression coronary artery calcification , progression carotid artery intima-media thickness , endothelial function , inflammation .</brief_summary>
	<brief_title>Atorvastatin Treatment Attenuate Progression Cardiovascular Disease Hemodialysis Patients</brief_title>
	<detailed_description>The effect statin treatment coronary artery calcification , carotid artery intima-media thickness , endothelial function never investigate hemodialysis patient . Regarding inflammation , present data hemodialysis patient derive small study short follow-up . We postulate atorvastatin would reduce progression coronary calcification carotid artery intima-media thickness , decrease inflammation , improve endothelial function . In prospective , control , randomize study , four hundred forty-six prevalent hemodialysis patient meet inclusion exclusion criterion randomize atorvastatin ( 20 mg/day first month ; increase 40 mg/day afterwards ) placebo arm ( arm consist 223 patient ) , completion baseline investigation . Randomization perform random permute block stratify accord dialysis center , age , sex , diabetic status , duration dialysis , high flux dialyser use , dialysate calcium level . Follow-up period twelve month . It estimate 446 patient would provide 90 % power two-sided , alpha error rate 5 % , detect significant difference treatment arm . Dropout rate expect 20 % , replace .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Calcinosis</mesh_term>
	<mesh_term>Vascular Calcification</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>age 18 80 year maintenance bicarbonate hemodialysis schedule thrice weekly , least 12 hours/week willingness participate study write informed consent serious lifelimiting comorbid situation , namely active malignancy , active infection , endstage cardiac , pulmonary , hepatic disease schedule live donor renal transplantation pregnancy lactate history coronary bypass grafting , acute myocardial infarction unstable angina pectoris confirm angiography within three month randomization presence absolute indication use lipid lower drug absolute contraindication lipid lower therapy accord investigator 's opinion history statin sensitivity adverse reaction statin receive lipidlowering agent within three month randomization uncontrolled hypothyroidism define TSH level high 1.5 time upper limit receipt investigational drug within 30 day randomization inability tolerate oral medication history significant malabsorption treatment steroid immunosuppressive drug alcohol abuse , drug abuse ALT and/or AST level three time upper limit normal symptomatic hepatobiliary disease unexplained CK &gt; 3 time upper limit normal range inability give inform consent mental incompetence psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>hemodialysis</keyword>
	<keyword>endothelial function</keyword>
	<keyword>coronary artery calcification</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>statin</keyword>
</DOC>